The Telegraph
Saturday , April 22 , 2017

Abbott to withdraw two stents

New Delhi, April 21 (PTI): Health-care major Abbott has decided to withdraw two types of stents from the Indian market in the wake of the drug price regulator's move to cap prices.

The company has applied to the National Pharmaceutical Pricing Authority (NPPA) seeking to withdraw the two types - the Alpine drug eluting stent and the Absorb dissolving stent.

An Abbott spokesperson said that following the NPPA's decision to fix a ceiling on the price of stents, the company "examined and re-examined" whether there was a sustainable way to make available the two latest technologies in India.

The company took into consideration the higher manufacturing costs and other associated costs of the two types of stents.

"We have determined it is not sustainable, and we have applied to the NPPA to withdraw these two stents," the spokesperson told PTI in an emailed statement.

The company said that presently, only a very small percentage of patients in India received Alpine and Absorb stents.

"While we are aligned with the government's intent for broad access to care, we're disappointed that the NPPA concluded there is no differentiation in coronary stent technology," Abbott said.

According to the company, it will continue to make available all other XIENCE coronary stent products within the ceiling price set by the NPPA.

"Alpine and Absorb will continue to remain available while the government reviews our application. There is no shortage of Abbott stents," the statement said.

 More stories in Nation

  • PDP-BJP battle over 'bullets'
  • Katappa apologises, asserts he's Tamil
  • 12 of 15 hottest towns in India
  • 60 drugs fail quality tests
  • UP police chief shunted
  • First IS conviction
  • SC junks Kohinoor appeal
  • Political science honour for Amartya
  • Aadhaar eyes child advocates
  • SC to scan BSF immunity
  • CM faces ally fire on cross
  • Hotel service charge tussle
  • Cop beaters set freed on probation
  • Maya turns to nephew
  • H-1B review changes the conversation